Cetuximab (Erbitux): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects
First approved by the FDA in February 2004, cetuximab became an important targeted therapy for metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN). Its efficacy in colorectal cancer is strongly influenced by molecular characteristics, particularly…